Zobrazeno 1 - 10
of 221
pro vyhledávání: '"S Welt"'
Publikováno v:
Cancer Research. 83:4880-4880
The concept that the B-cell Receptor Complex (BCRC) initiates the dominant driver pathway in leukemia-lymphoma is clinically validated. However, the BCRC has been overlooked as a therapeutic target due to homology between the BCRC’s membrane Ig (mI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c101aeee30d580674d5ae969867c80ff
https://doi.org/10.1158/1538-7445.am2023-4880
https://doi.org/10.1158/1538-7445.am2023-4880
Autor:
Frank T. Burbrink, Kahmun Lo, Maya Juman, Sara Ruane, Edward A. Myers, India Futterman, Gregory E. Schneider, Sara Yuen, Ronald A. Nussbaum, Rachel S. Welt, Christopher J. Raxworthy
Publikováno v:
Systematics and Biodiversity. 16:229-244
Although many wide-ranging taxa occur in Madagascar, phylogeographic studies for most of these species are still lacking. This is especially the case for snakes, where of more than 100 endemic species, the population structure of only two species has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05af691a9373949250137a2813c35f85
https://doi.org/10.1080/14772000.2017.1375046
https://doi.org/10.1080/14772000.2017.1375046
Publikováno v:
Cancer Immunology Research. 9:PO020-PO020
The concept that the B-cell Receptor Complex (BCRC) initiates a driver pathway in leukemia-lymphoma has been validated by clinical data. Previously, we reported the generation of a first-in-class antibody, mAb4, to a neo-epitope specific to the BCRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::961b7d2ecc28dffcaea7b9fa93e17b63
https://doi.org/10.1158/2326-6074.tumimm20-po020
https://doi.org/10.1158/2326-6074.tumimm20-po020
Autor:
David Kostyal, Jonathan Welt, Sydney Welt, Yamuna D. Gangadharan, Virginia Raymond, Rachel S. Welt
Publikováno v:
Oncotarget
The concept that the B-cell Receptor (BCR) initiates a driver pathway in lymphoma-leukemia has been clinically validated. Previously described unique BCR Ig-class-specific sequences (proximal domains (PDs)), are not expressed in serum Ig (sIg). As a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8ed9c3491624a8ea6c47d85366045
https://doi.org/10.18632/oncotarget.12506
https://doi.org/10.18632/oncotarget.12506
Publikováno v:
Blood Cancer Discovery. 1:PO-59
Introduction: The concept that the B-cell receptor complex (BCRC) initiates a driver pathway in leukemia-lymphoma has been validated by clinical data. However, the BCRC has been overlooked as a therapeutic target due to homology between the BCRC's me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae32d4565c7556e5cbe0fe8ec4bc6285
https://doi.org/10.1158/2643-3249.lymphoma20-po-59
https://doi.org/10.1158/2643-3249.lymphoma20-po-59
Publikováno v:
AoB Plants
Climate change can have widespread and devastating impacts, but little is known about the effects of this change on the genetics of natural populations. We examined the genetics of two populations of an annual plant (Brassica rapa) before and after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4901f46393a7f4ef91bea321585632
https://pubmed.ncbi.nlm.nih.gov/25818074
https://pubmed.ncbi.nlm.nih.gov/25818074
Publikováno v:
Medical oncology (Northwood, London, England). 29(3)
Cell surface transmembrane signaling receptors EGFR, HER3, and HER4 are activated by ligand-binding-mediated dimerization and phosphorylation. In contrast, HER2 amplification promotes signaling by increasing homo/heterodimerization and ligand binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba88ede6262e1afbd43e0b73d9e916a
https://pubmed.ncbi.nlm.nih.gov/21769502
https://pubmed.ncbi.nlm.nih.gov/21769502
Autor:
J. Humm, D. Shochat, Lloyd J. Old, A. Turner, A. M. R. Haines, G. T. Yarranton, A P Farnsworth, S. Welt, P. Antoniw, David J. King, J. Mackintosh, A. Mountain
Publikováno v:
British Journal of Cancer
The monoclonal antibody A33 recognises a tumour-associated antigen on human colorectal carcinoma, and has undergone preliminary evaluation in the clinic where selective localisation to hepatic metastases has been demonstrated [Welt et al. (1994) J. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6905aee8243907e3e19ba62bd260daa1
https://doi.org/10.1038/bjc.1996.395
https://doi.org/10.1038/bjc.1996.395
Publikováno v:
Protein Phosphorylation in Human Health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91efd03b1c572679899db5be79708647
http://www.intechopen.com/articles/show/title/modulation-of-her2-tyrosine-threonine-phosphorylation-and-cell-signalling
http://www.intechopen.com/articles/show/title/modulation-of-her2-tyrosine-threonine-phosphorylation-and-cell-signalling
Autor:
S, Welt, C R, Divgi, N, Kemeny, R D, Finn, A M, Scott, M, Graham, J S, Germain, E C, Richards, S M, Larson, H F, Oettgen
Publikováno v:
Journal of Clinical Oncology. 12:1561-1571
PURPOSE A phase I/II study was designed to determine the maximum-tolerated dose (MTD) of iodine 131-labeled monoclonal antibody (mAb) A33 (131I-mAb A33) administered intravenously, its limiting organ toxicity, and its radioisotope retention in tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6e869ba786f2d48da05bad628a8d48
https://doi.org/10.1200/jco.1994.12.8.1561
https://doi.org/10.1200/jco.1994.12.8.1561